Physician

H J Wedner, MD

According to 2025 Medicare claims, H. Wedner, MD (NPI: 1386661809) practices allergy/immunology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Louis, MO. This provider's primary affiliated billing organization is WASHINGTON UNIVERSITY (NPI: 1992746903; TIN: 430653611) and primary practice location at 63141-6350.

Wedner's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 359 traditional Medicare patients, billed 64,226 HCPCS/CPT codes, and received $1,313,864 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,305 prescription claims across 217 beneficiaries totaling $10,271,210 in drug costs, led by Kalbitor (Ecallantide). DME data shows 304 claims. Open Payments data shows 86 records totaling $175,017. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $379,908 to $1,313,864. Similarly, Part D prescription costs have risen steadily, from $4,754,136 to $10,271,210. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $14,747 and ending at $7,443.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	458	20,310	$379,908
2016	485	30,259	$461,227
2017	485	28,398	$469,182
2018	482	34,379	$692,274
2019	411	36,205	$729,457
2020	469	56,852	$1,130,094
2021	435	56,754	$1,174,101
2022	420	45,244	$960,094
2023	433	56,537	$1,088,441
2024	359	64,226	$1,313,864

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	198	1,558	$4,754,136
2016	212	2,054	$4,853,439
2017	257	2,181	$6,438,065
2018	245	1,908	$4,493,793
2019	228	2,029	$6,910,803
2020	217	1,936	$6,556,393
2021	210	1,815	$8,303,896
2022	214	2,113	$8,733,917
2023	226	2,146	$8,186,184
2024	217	2,305	$10,271,210

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	465	$331,570
2016	N/R	566	$531,851
2017	14	641	$517,597
2018	23	756	$727,172
2019	12	787	$711,655
2020	11	630	$530,037
2021	N/R	541	$614,442
2022	N/R	562	$568,741
2023	N/R	425	$429,385
2024	N/R	304	$394,410

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	123	232	$90
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	98	293	$43
J0897	Injection, denosumab, 1 mg	52	3,180	$20
96366	Infusion into a vein for therapy, prevention, or diagnosis, each additional hour	39	236	$14
96372	Injection of drug or substance under skin or into muscle	73	187	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kalbitor	Ecallantide	15	394	$4,488,239
Takhzyro	Lanadelumab-Flyo	35	994	$1,421,210
Ayvakit	Avapritinib	23	750	$977,975
Haegarda	C1 Esterase Inhibitor	13	364	$638,815
Ruconest	C1 Esterase Inhibitor, Recomb	11	282	$495,537

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	30	$126,166
J1557	Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	30	$88,081
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	29	$84,251
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	20	$42,775
J1558	Injection, immune globulin (xembify), 100 mg	N	N/R	12	$38,361

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	71	$87,237	Blueprint Medicines Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	15	$87,780	GlaxoSmithKline, LLC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for H. J. Wedner, MD?

Tedicare shows public-source Medicare data for H. J. Wedner, MD (NPI 1386661809), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does H. J. Wedner, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to H. J. Wedner, MD?

H. J. Wedner, MD is linked to WASHINGTON UNIVERSITY (billing NPI 1992746903) in the available physician profile data.

Does H. J. Wedner, MD have Open Payments data?

H. J. Wedner, MD has 86 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.